Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine in Chronic Myelogenous Leukemia
NCT00006364Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1999
- Primary completion
- Sep 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in chronic myelogenous leukemia (CML), sponsored by National Cancer Institute. Started Nov 1999; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00006364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006364.